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A B S T R A C T
To investigate the effect of supersaturation induced by micelle formation during dissolu-
tion on the bioavailability of itraconazole (ITZ)/Soluplus® solid dispersion. Solid dispersions
prepared by hot melt extrusion (HME) were compressed into tablets directly with other ex-
cipients. Dissolution behavior of ITZ tablets was studied by dissolution testing and the
morphology of micelles in dissolution media was studied using transmission electron mi-
croscopy (TEM). Drug transferring from stomach into intestine was simulated to obtain a
supersaturated drug solution. Bioavailability studies were performed on the ITZ tablets and
Sporanox® in beagle dogs. The morphology of micelles in the dissolution media was ob-
served to be spherical in shape, with an average size smaller than 100 nm.The supersaturated
solutions formed by Soluplus® micelles were stable and no precipitation took place over a
period of 180 min. Compared with Sporanox®, ITZ tablets exhibited a 2.50-fold increase in
the AUC(0–96) of ITZ and a 1.95-fold increase in its active metabolite hydroxyitraconazole (OH-
ITZ) in the plasma of beagle dogs. The results obtained provided clear evidence that not
only the increase in the dissolution rate in the stomach, but also the supersaturation pro-
duced by micelles in the small intestine may be of great assistance in the successful
development of poorly water-soluble drugs. The micelles formed by Soluplus® enwrapped
the molecular ITZ inside the core which promoted the amount of free drug in the intesti-
nal cavity and carried ITZ through the aqueous boundary layer (ABL), resulting in high
absorption by passive transportation across biological membranes. The uptake of intact mi-
celles through pinocytosis together with the inhibition of P-glycoprotein-mediated drug efflux
in intestinal epithelia contributed to the absorption of ITZ in the gastrointestinal tract. These
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formation, may be of great assistance to the successful development of poorly water-
soluble drugs.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
With an increasing number of active pharmaceutical ingredi-
ents (APIs) belonging to BCS II, aqueous solubility has become
a critical issue since BCS II APIs must first dissolve in the gas-
trointestinal fluid prior to being absorbed to exert a therapeutic
effect. As a result, increasing the solubility of poorly water-
soluble APIs is of major importance.
ITZ is a typical orally active, broad-spectrum, triazole an-
tifungal drug belonging to BCS II and exhibits low oral
bioavailability due to its poor aqueous solubility [1]. The solu-
bilities of ITZ in simulated gastric fluid (SGF) at pH 1.2, deionized
water and simulated intestinal fluid (SIF) at pH 6.8 were about
3.9 ± 0.7, 0.002 and 0.003 μg/ml, respectively [2]. As a result, the
bioavailability of crystalline ITZ after oral administration is far
below that of Sporanox® [3]. Several investigations have re-
ported that the poor bioavailability of ITZ was due to its poor
solubility and rapid drug precipitation during dissolution [4,5].
As a result, enhancing the apparent solubility and dissolu-
tion rate of ITZ is necessary to improve its oral bioavailability.
Since drugs in a state of supersaturation are metastable, or
kinetically soluble in solution at a concentration above their
thermodynamic equilibrium solubility, formulation technolo-
gies that can induce supersaturation may be of great assistance
to the successful development of poorly water-soluble drugs
[6]. Solid dispersion is one of the most promising strategies to
improve solubility and bioavailability of poorly water-soluble
drugs by dispersing the poorly soluble drugs as an amor-
phous state in the hydrophilic polymers [7].
Polymeric micelles are formed by self-assembly of amphi-
philic polymers, with a hydrophobic core as a reservoir for
lipophilic drugs [8]. Depending on the physico-chemical prop-
erties of the drug as well as those of the polymer chains forming
the micellar structure, the core of PMs is capable of solubiliz-
ing considerable amounts of drug molecules which otherwise
would precipitate in the aqueous fluids of the GI tract. They
can increase the bioavailability of poorly water-soluble drugs
and provide an increasingly popular way to improve the oral
absorption of poorly water-soluble APIs [9].
Tablets account for more than 80% of all dosage forms ad-
ministered to humans.The principal reasons for their continued
popularity include their ease of manufacture, convenience of
dosing, and stability compared with other dosage forms [10].
The oral route is often preferred for drug administration, due
to its acceptability and convenience. Also, it is much safer com-
pared with other routes of administration. In this work, the
main benefit of tableting was to protect the stability of the solid
dispersions.The direct compression method was preferred due
to its convenience and efficiency, because no special manu-
facturing facilities or granulation processes were required for
the preparation of tablets. These tablets, made by a low-cost
direct compression method, can disintegrate rapidly when in
contact with gastric fluid in the stomach and have sufficient
mechanical integrity to withstand transportation and storage
without any substantial structural damage.
The preparation of Sporanox® involved dissolving the drug
and hydroxypropyl cellulose completely in a mixed solution
of dichloromethane and denatured ethanol, and then spray-
ing the solution onto the surface of sugar spheres in a fluidized-
bed granulator.The pellets were then coated with polyethylene
glycol 20,000 in methylene chloride and denatured ethanol so-
lution. The ITZ in the final product was in an amorphous form
to achieve the required oral bioavailability [3,11,12].
The first objective of this study was to investigate the sta-
bility and dissolution behavior of ITZ tablets. The second
objective was to investigate the supersaturation induced by the
micelles in simulated gastrointestinal fluid tract which pro-
duced an increase in the extent and routes of absorption that
contributed to the high bioavailability of ITZ compared with
Sporanox®.
2. Materials and methods
2.1. Materials
ITZ (purity 99.4%) was purchased from Shandong Shouguang
Pharmaceutical Company (Shandong, China). Soluplus® was
kindly provided by BASF (Shanghai, China). Sporanox® cap-
sules (lot number: 120221224) were obtained from Xian Janssen
Pharmaceutical Ltd. (Xian, China). ITZ and the active metabo-
lite, OH-ITZ (purity more than 99%), were purchased from J&K
Scientific Ltd. (Shanghai, China) and used as reference sub-
stances. All reagents were of analytical or chromatographic
grade. The beagle dogs used for in vivo evaluation were pur-
chased from the Military Medical Science Research Institute
(Beijing, China). The experimental protocol was evaluated and
approved by the University Ethics Committee for the use of ex-
perimental animals and conformed to the Guide for Care and
Use of Laboratory Animals.
2.2. Sample preparation
2.2.1. Preparation of the tablets
The ITZ tablets were prepared by hot melt extrusion (HME) with
direct compression. ITZ/Soluplus® solid dispersions were pre-
pared by HME using a co-rotating twin-screw extruder (Coperion
Keya Co., China). Physical mixtures were mixed uniformly in
a mixer prior to the extrusion. The temperatures of four zones
were set at 140, 160, 160, and 160 °C, separately. Feeding and
extrusion rates were both carried out at 3.5 Hz.The drug content
in the solid dispersions was 40% (w/w).
The milled extrudates and other excipients were placed in
a mixing machine to obtain a homogeneous powder. The
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amounts of the extrudates, microcrystalline cellulose (MCC),
croscarmellose sodium, talc and magnesium stearate were 50%,
42.5%, 5%, 2% and 0.5%, respectively. The mixed powders were
placed in the hopper of the rotary tablet machine and then com-
pressed into tablets. The hardness of the tablets was between
100 and 120 N to meet the demands of transportation and
storage conditions throughout the whole experiment. Each of
the tablets contained approximately 100 mg ITZ.
2.3. Characterization in vitro
2.3.1. Differential scanning calorimetry
Differential scanning calorimetry (DSC) measurements were
performed using a DSC 1 instrument (Mettler Toledo, Switzer-
land) equipped with a refrigerated cooling system. Each sample
(approximately 4 mg, accurately weighed) was placed in her-
metically sealed aluminum pans and then heated over a
temperature range of 20–200 °C at a heating rate of 10 °C/min
in an atmosphere of nitrogen. A pin hole was made in the lid
to allow the escape of moisture.
2.3.2. HPLC analysis for ITZ
An HPLC method was used to quantifying ITZ. Data were col-
lected and integrated using EZChrom Elite® software. The
column was Thermo® Hyprsil BDS 3 μm C18, 100 × 4.6 mm
(Thermo®, USA). An isocratic solvent system consisting of 40:60
(v/v) acetonitrile–deionized water containing 0.02 mol/l
tetrabutylammonium hydrogen sulfate was used at a flow rate
of 1 ml/min. The injection volume is 10 μl. The peaks were de-
tected at a wavelength of 225 nm (λmax). The retention time of
ITZ was approximately 8 min. The HPLC assay for related sub-
stances was performed according to the USP35.
2.3.3. Dissolution testing of tablets
Dissolution tests were performed under non-sink conditions
according to the USP 35 method 2 using a ZRS-8G dissolution
test system (Tianda Tianfa, China). In order to investigate the
dissolution of the tablets, each of the tablets (equivalent to
100 mg ITZ) was directly added to a series of different disso-
lution media at a temperature of 37 °C with a paddle rotation
speed of 75 rpm.Then, six-milliliter samples were removed and
immediately replaced with fresh dissolution medium at 5, 10,
20, 30, 45, and 60 min. Samples were passed through 0.22 μm
Millipore filter membranes. After discarding the first 2 ml, the
filtrates were analyzed using HPLC. Analyses were carried out
in triplicate.
2.3.4. Determination of critical micelle concentration
The critical micelle concentration (CMC) was determined by
a fluorescence probe technique using pyrene as a fluores-
cence probe.
To prepare sample solutions, 100 μl pyrene (approximately
1 × 10−3 mol/l) in acetone were added to each of a series of 10 ml
volumetric flasks and acetone was subsequently removed by
evaporation under nitrogen gas flow, followed by vacuum drying
for 2 h to evaporate the residual acetone at room tempera-
ture. The final concentration of pyrene in the solution was
adjusted to 1.0 × 10−7 M. Ten milliliter samples of a series of dif-
ferent concentrations of the polymer solution (0.05, 0.1, 0.5, 1,
5, 10, 50, 100 mg/l) were added to the volumetric flasks. The
combined solution of pyrene and polymer was sonicated for
30 min and allowed to reach equilibrium by cooling over-
night at room temperature before measurement. Fluorescence
excitation spectra were recorded at an emission wavelength
of 390 nm.The emission and excitation wavelengths were from
350 nm to 300 nm in steps of 1 nm using a Microplate Reader
(BIO-RAD 680, Bio-Rad Laboratories, Inc, USA). CMC was mea-
sured from the onset of a rise in the intensity ratio of peaks
at 338 nm to peaks at 335 nm in the fluorescence spectra of
pyrene plotted versus the logarithm of polymer concentration.
2.3.5. Gel Permeation Chromatography analysis
The splitting of the polymer chains was measured by gel per-
meation chromatography (GPC) analysis. Number average
molecular weight (Mn), weight average molecular weight (Mw)
and polydispersity index (PDI = Mw/Mn) of Soluplus® and
Soluplus® extrudates were measured using Waters 1515 GPC
with three Styragel columns (Waters Corp; 105, 104, and 103)
in tandem and a 2414 differential refractive index detector. DMF
containing 0.1 M LiBr was selected as the eluent at a flow rate
of 1.0 ml/min at 35 °C. The sample concentrations were ap-
proximately 2 mg/ml.
2.3.6. Transmission electron microscopy
The morphology of the micelles in simulate gastrointestinal
fluid was studied using transmission electron microscopy (TEM).
After passing through a 0.22 μm Millipore filter, a drop of micelle
solution was immediately spread on a copper grid for about
20 min and the excess liquid was removed with filter paper.
Two percent aqueous phosphotungstic acid was then dropped
onto the grid for negative staining for 2 min. Samples were dried
under room temperature for 6 hours and viewed using a JEM-
2100 TEM (JEOL, Tokyo, Japan).
2.3.7. Predicting the precipitation of ITZ upon entry in the
small intestine
To simulate the transfer of ITZ out of the stomach into the in-
testine, a transfer model was employed [13]. A solution of the
drug in hydrochloric acid at pH = 1.2 was continuously pumped
into a phosphate buffer at pH = 6.8, and the drug preci-
pitation in the acceptor medium was examined using
concentration–time measurements. A peristaltic pump (BT100-
2J, Longer Pump, China) was used to transfer the donor phase
(hydrochloric acid at pH = 1.2 containing dissolved drug) into
a dissolution vessel containing 500 ml phosphate buffer at
pH = 6.8 as the acceptor phase. The transfer rate (3.0 ml/min)
represented the physiological flow rate out of the stomach.The
acceptor phase medium was maintained at 37 °C. To examine
the influence of intestinal motility on drug precipitation, a
paddle rotation speed of 75 rpm was used in the acceptor phase.
Samples (1.5 ml) were withdrawn at predetermined intervals
(5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 105, 120,
135, 150, 165 and 180 min) during transportation.These samples
were passed through 0.22 μm Millipore filters and then ana-
lyzed by HPLC. All tests were performed in triplicate, and data
are presented as the mean ± S.D.
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2.4. In vivo studies
2.4.1. Animal experiments
Six male beagle dogs (10 ± 0.5 kg) were kept in an air-conditioned
experimental animal room at a temperature of 22 ± 2 °C and
a relative humidity of 50 ± 10%. Access to water and labora-
tory chow was provided ad libitum. Dogs were allowed to
acclimatize for at least 7 days and then fasted, but allowed free
access to water for 12 hours prior to the experiment. Dogs re-
ceived two different treatments with ITZ tablets and Sporanox®
at 2-week intervals in a randomized two-way crossover study.
Blood samples (400 μl) were collected and transferred into hepa-
rinized glass tubes at 0.5, 0.45, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60,
72 and 96 hours after administration. Blood samples were cen-
trifuged (4000 rpm, 10 min, 4 °C) and the plasma samples were
stored at −80 °C until analysis.
2.4.2. Analysis of ITZ in plasma
The samples for UPLC-ESI-MS/MS analysis were prepared by
liquid–liquid extraction. One hundred microliters of plasma
sample, 50 μl of internal standard (loratadine 50 ng/ml in metha-
nol) and 100 μl of methanol were added into each centrifuge
tube. After vortex-mixing for 1 min, 50 μl of potassium
dihydrogen phosphate buffer (pH = 8.4) and 2 ml of tert-butyl
methyl ether were added and vortex-mixed for 10 min to extract
ITZ. After centrifuging at 4000 rpm for 10 min, the organic layer
was transferred to another tube and evaporated under a light
stream of nitrogen at 40 °C. This extraction was repeated, and
the organic layer residues were reconstituted in 100 μl metha-
nol before vortexing for 10 min and centrifuging at 12,000 rpm
for 10 min.
Chromatography was performed on an ACQUITYTM UPLC
system (Waters Corp., Milford, MA, USA) with a column tem-
perature of 40 °C and an autosampler temperature of 10 °C.
Samples (5 μl) were eluted with a mobile phase consisting of
acetonitrile and 0.1% (w/w) methanolic acid solution (50:50, v/v)
from an ACQUITY UPLCTM BEH C18 column (50 mm × 2.1 mm
i.d., 1.7 μm; Waters Corp., Milford, MA, USA). Validation of the
analytical methods for both ITZ and OH-ITZ under the se-
lected conditions showed that the chosen method was of
acceptable precision and accuracy with a linear response of
10–1000 ng/ml. Individual plasma concentrations versus time
data for ITZ and OH-ITZ were analyzed using DAS 2.0 software.
3. Results
3.1. Evaluation of tablet properties
3.1.1. Stability of amorphous ITZ
Fig. 1 shows the DSC spectra of the ITZ, Sporanox® and ITZ
tablets. Pure itraconazole showed an endothermic peak at
173 °C. Sporanox® showed two endothermic peaks at 59 °C and
186 °C, corresponding to the melting point of PEG and
itraconazole, respectively [14], while ITZ tablets showed no
melting endotherms, indicating that amorphous ITZ was
obtained.
3.1.2. Dissolution properties
The dissolution profiles of ITZ tablets and Sporanox® in dif-
ferent dissolution media are shown in Fig. 2. The dissolution
media were hydrochloric acid at pH 1.2 (USP 35), acetate buffer
at pH 4.5 (USP 35), phosphate buffer at pH 6.8 (USP 35) and SGFsp,
respectively. The composition of SGFsp dissolution medium,
simulating gastric conditions in the fasted state was 2 g NaCl,
3.2 g pepsin and 7 ml HCl in 1000 ml water, and the medium
had a pH of about 1.2. Result (Fig. 2) shows that the dissolu-
tion rates and extents of the ITZ tablets were much higher
compared to Sporanox®. For tablets dissolved in hydrochloric
acid at pH 1.2, the percentage release of ITZ was approxi-
mately 98% in 10 min while the corresponding result for
Sporanox® was only about 14%, indicating that ITZ in the tablets
Fig. 1 – DSCs of (a) Itraconazole Tablets (6 months at 40 °C/RH75%), (b) Sporanox® (12 months at 25 °C/RH60%), (c) Physical
mixtures (same proportion as tablets), (d) Crystalline Itraconazole.
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dissolved immediately when they came into contact with the
hydrochloric acid at pH 1.2. A similar dissolution behavior of
ITZ tablets was obtained in the experiment conducted in the
SGFsp. The maximal dissolution extent of ITZ tablets in acetate
buffer and phosphate buffer was 78.66% and 71.71%, respec-
tively. However, the maximal dissolution extent of Sporanox®
was 4.90% and 5.36%, which were much lower than that of ITZ
tablets.
It was concluded that itraconazole can be largely solubi-
lized by Soluplus® in these three media, the order of the
solubilization capacity for these media was: hydrochloric acid
at pH 1.2 > acetate buffer at pH 4.5 > phosphate buffer at pH
6.8.
3.1.3. Evaluation of micelle properties
The presence and the morphology of the micelles in SGFsp and
SIF (USP 35) were examined by TEM. As can be seen from the
TEM analysis, the micelles were spherical in shape with uniform
smooth surfaces. It has been reported that the mean particle
size of blank Soluplus® micelles is about 65 nm [15]. Accord-
ing to Fig. 3, it can be seen that the size of the micelles was
approximately 70 nm in the simulated gastric fluids, while the
size of micelles was only 50 nm in the SIF. It can be con-
cluded that the hydrophilic domain (polyethylene glycol) of
Soluplus® served as a flexible outer shell of the core–shell struc-
ture in aqueous solution while the hydrophobic domain
(polyvinyl caprolactam) formed the solid inner core, which
would entrap the hydrophobic drug in its interior.
3.2. Critical micelle concentration of Soluplus®
Fig. 4 shows the fluorescence excitation spectra of pyrene at
various concentrations of Soluplus® and Soluplus® extrudates.
The fluorescence intensity increased with the increased polymer
concentration, which indicates self-assembly of Soluplus® in
water [16,17]. The CMC was presented as the intensity ratio of
I338/I335 versus the logC of Soluplus® for the pyrene excitation
spectra, as shown above. The critical micelle concentration
values of Soluplus® and Soluplus® extrudates were calcu-
lated to be 1.93 mg/L and 4.24 mg/l at 37 °C, respectively. It is
speculated that the difference in CMC values between Soluplus®
and Soluplus® extrudates was due to partial splitting of chains.
The splitting of the polymer chains was measured by gel
permeation chromatography (GPC) analysis. Results showed that
the polydispersity indexes (PDI = Mw/Mn) for blank Soluplus®
and blank Soluplus® extrudates were 1.442 and 1.802, respec-
tively, and the retention times were 23.337 min and 23.400 min,
respectively. As expected, the overall results of the GPC data
demonstrated that trace amounts of chains were split during
the extrusion process.
Fig. 5 shows the formation of micelles by ITZ/Soluplus® solid
dispersion and ITZ/Soluplus® physical mixers. Lower CMC values
are generally due to the presence of highly hydrophobic
domains in the micelle core which denote greater stability of
the micelles [18]. In this study, the low CMC value (4.24 mg/l)
of Soluplus® extrudates demonstrated that Soluplus® through
the HME process was able to form stable micelle systems.
3.3. Transfer experiments of ITZ
In vitro drug precipitation under pH = 6.8 phosphate buffer con-
ditions was examined since the possibility of drug precipitation
upon entry into the small intestine may also affect the amount
of drug available for absorption through the intestinal mucosa
[19]. Fig. 6 shows the concentration–time profile of ITZ
Fig. 2 – Comparison of drug release profiles between ITZ
tablets and Sporanox® in different dissolution media.
Fig. 3 – TEM images of ITZ Soluplus® micelles in the SGFsp
(a) and SIF (b).
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transferred from hydrochloric acid at pH = 1.2 to a phosphate
buffer at pH = 6.8.
It can be seen that the maximum concentration observed
in phosphate buffer at pH = 6.8 during the experiment and its
corresponding Tmax was about 50 min. Soluplus® kept drug from
precipitating in the phosphate buffer at pH = 6.8 for at least
180 min, while supersaturation and then little precipitation of
ITZ were observed for Sporanox®. The maximum concentra-
tions in the acceptor phase media were 15.60 μg/ml and
11.44 μg/ml, respectively, while the final equilibrium concen-
trations were 13.94 μg/ml and 7.32 μg/ml, respectively.
3.4. In vivo performance
Fig. 7 shows the plasma concentration–time curves of ITZ and
its primary active metabolite, OH-ITZ in beagle dogs, after oral
administration of ITZ tablets and Sporanox® in a randomized
two-way crossover study. The ITZ tablets increased the rela-
tive bioavailability of ITZ and OH-ITZ significantly compared
with Sporanox®. The pharmacokinetic parameters of ITZ and
OH-ITZ were listed in Table 1. There was a 1.50-fold increase
in the AUC(0–t) of ITZ and a 0.95-fold increase in its active
metabolite, OH-ITZ, compared with Sporanox® in plasma ac-
cording to the bioequivalence results calculated using DAS 2.0
software. For ITZ, the mean Cmax was 1.33-times higher than
that of Sporanox® while the mean Tmax was 1.5 hours earlier
and, for OH-ITZ, the mean Cmax was 1.28-times higher and the
mean Tmax was 0.6 hour earlier than that of Sporanox®.The con-
fidence intervals of the equivalence analysis (ABE): [1-2α] were
141.3%–332.2% and 86.6%–323.2% for ITZ and OH-ITZ, respec-
tively. The available data demonstrated that the two dosage
forms (the ITZ tablet and Sporanox®) were not bioequivalent
and the ITZ tablet was outside of the BE range (80.0%–120.0%).
4. Discussion
4.1. Characterization of ITZ in preparations
The purpose of HME was to obtain an amorphous state of API
that dispersed homogeneously in the amphiphilic carrier. The
lack of a melting peak in the DSC of the milled powders of ITZ
tablets indicated that the drug in the ITZ tablets was present
in an amorphous state rather than a crystalline form under
stress conditions (40 °C/75% RH) for 6 months. It can be con-
cluded that the amorphous state dispersion in the tablets was
well protected during storage, which would ensure the main-
tenance of the dissolution profiles and the therapeutic effect.
Also, the presence of crystalline ITZ in the DSC of Sporanox®
confirmed that the method used in the present study had an
advantage in stability of amorphous state over the cosolvent
evaporation method which was used in the Sporanox®
preparation.
4.2. Effects of Soluplus® on dissolution and
supersaturation under usual dosing conditions (100 mg)
The proposed drug solution upon coating (cosolvent evapora-
tion) and controlled drying of the coated beads produced an
amorphous form of drug in HPMC that allows quick dissolu-
tion of the drug from Sporanox® upon reaching the stomach
[3,11]. However, the dissolution rate of Sporanox® was far lower
than that of ITZ tablets in the first 5 min. It can be concluded
that, in a fasted state, the pellets would pass into the duode-
num without being fully dissolved. According to the dissolution
curve, it can be seen that the drug could not continue to dis-
solve from the pellets, since the dissolution of ITZ in Sporanox®
in acetate buffer at pH = 4.5 and phosphate buffer at pH = 6.8
was much lower than that of the tablets, and the changes in
conditions and pH may lead to precipitation of ITZ. It can be
inferred that it was one of the reasons for the higher oral
bioavailability of the tablets compared with Sporanox®.
So, it can be presumed that with the absorption of ITZ in
the GI tract, the drug continues to be released from the mi-
celles during the whole absorption period. Results showed that
Soluplus® acted as a supersaturation inducer in an attempt to
prevent drug precipitation upon GI fluid dilution and change
in pH values in the gastrointestinal tract. Once the tablet comes
in contact with gastric juice, the drug is completely dissolved
in the first 5 min. As a result, ITZ existed as the molecular state
and ionic state of ITZ dissolved in gastric juice as well as the
Fig. 4 – Fluorescence intensity (I338/I335) ratio of pyrene as a
function of the logarithm of the Soluplus® concentration.
(a) Soluplus® (b) Soluplus® extrudates.
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molecular ITZ that entrapped in the micelles. When passing
into the small intestine, the drug released from micelles con-
tinuously can be absorbed immediately by the gastrointestinal
tract.
It has been reported that nonionic surfactants possess a
greater ability to dissolve poorly water-soluble drugs [20]. In
addition, the strength of the intermolecular interactions
between ITZ and polymeric stabilizers largely determines the
extent of supersaturation in aqueous media and the stability
of the supersaturated solutions [4]. In this study, Soluplus®
served not only as a functional carrier but also as an inhibi-
tor of ITZ molecular precipitation due to the self-assembly
ability of Soluplus® which would enwrap the drug inside the
core of the micelles and prevent the drug from precipitating
during absorption. The solubilization system is thermody-
namically stable, and a CMC value less than 135 mg/ml should
be regarded as a guide due to the fact that lower CMC values
mean greater resistance to the effects of dilution and, there-
fore, greater stability [21]. In recent years, researchers have
shown that the solubilizing agent was evenly distributed in poly-
meric micelles. Solubilization of the micelles is a dynamic
equilibrium procedure, constantly involving disintegration and
reforming [22]. It appears that the excellent apparent solubil-
ity property was a result of the formation of the polymeric
micelles and the amphiphilic nature of Soluplus®.
Since supersaturation is known to be a metastable state [23],
the apparent solubility of supersaturated Soluplus® micelle so-
lutions was 81.55 μg/ml in acetate buffer at pH = 4.5 and
74.40 μg/ml in phosphate buffer at pH = 6.8. Furthermore, the
micelles could keep the drug from precipitating for at least 4
hours. In general, the gastric pH in young, healthy, fasting
humans who have taken 200 ml water varies within the range
pH 1.5–5 [24]. The high apparent solubility indicates that the
dissolved drug could be kept in the micelles and prevented from
precipitating without limitation of pH values under normal
dosing conditions. The presence of pepsin did not affect the
rate and extent of dissolution of the tablets due to the fact that
the dissolution curve for SGFsp is similar to that of hydrochlo-
ric acid at pH 1.2. Therefore, the achlorhydric population with
a gastric pH > 5 or even higher may obtain a much better thera-
peutic effect compared with Sporanox®. It would, therefore, be
Fig. 5 – Different dissolution processes between ITZ/Soluplus® solid dispersion and physical mixers.
Fig. 6 – Measured ITZ concentration of ITZ tablets and
Sporanox® in phosphate buffer at pH = 6.8 (n = 3 ± SD)
using a paddle speed of 75 rpm at a transfer rate 3 ml/min.
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highly desirable to have pharmaceutical formulation which can
be administrated to a patient, independently of the food intake.
However, further research is needed to confirm this.
The apparent solubility of the physical mixture (ITZ/
Soluplus = 40/60) was 4.74 μg/ml compared with that of
crystalline ITZ, 4.92 μg/ml, in hydrochloric acid pH = 1.2 (USP
35) after shaking for 72 h at a temperature of 37 °C. So, this
means that, ITZ can barely be solubilized by Soluplus® in its
crystalline state.The different solubility properties between the
physical mixtures and solid dispersions were mainly due to
the fact that the crystalline state needed to overcome crystal
lattice energy upon dissolution. The crystalline nature of ITZ
can be disrupted by solid-state dispersion of the drug into water
soluble carrier molecules which replace the drug molecule in
the crystal lattice. This results in lower lattice tensile strength
and particles with lower lattice tensile strength are easier to
dissolve. Therefore, the amorphous state of the drug through
HME in the solid solution played a crucial role in obtaining the
supersaturated micelle solutions.
4.3. In vivo implications of pharmacokinetic data
Comparative statistical analysis showed that the ITZ tablets
were not bioequivalent to Sporanox®.The ITZ tablets have been
shown to achieve better bioavailability than Sporanox® in beagle
dog studies. It is also worth noting that the Tmax of ITZ tablets
was earlier than that of Sporanox®, mainly due to the rapid
and complete dissolution of the tablets in the stomach and the
supersaturation state maintained in the intestinal cavity.
The permeability of biological membranes is a key deter-
minant of drug pharmacokinetics. Fig. 8 shows how micelles
can permeate the intestinal membrane. The transportation of
a drug across the intestinal membrane is a complex transfer
process involving several mechanisms: (1) transcellular per-
meation through the epithelial cells that consists of passive
transcellular and carrier-mediated permeation; (2) paracellular
permeation passing between the cells which can pass through
the tight junction channels between adjacent epithelial cells
and; (3) uptake of intact micelles through pinocytosis which
refers to transport into a cell [25].
Both passive transcellular and carrier-mediated processes
coexist and contribute to ITZ transport activities across bio-
logical membranes. Passive diffusion through the lipid bilayer
portion of a biological membrane is suggested to be the domi-
nant route. The ABL is adjacent to a membrane that can be a
permeation barrier for highly lipophilic drugs. Due to the hy-
drophilicity of PEG cores that remained outside the assembled
micelles, drug molecules inside the micelles are carried through
the ABL covering on the small intestinal villi, arriving at the
surface of the microvilli. Here, drugs are gradually released
from micelles and pass through the microvilli into the cells
of the epithelial mucosa of the small intestine (the micelle
shell remains in the intestinal cavity). The oral administra-
tion of ITZ is also complicated by the multidrug transporter
P-gp in the small intestine since ITZ is a known substrate of
the P-gp efflux system. However, the increased dissolution rate
and solubility provided a higher luminal concentration that
could more efficiently saturate the intestinal efflux and/or me-
tabolism of ITZ. In addition, it has been reported that Soluplus®
has a negligible impact on P-gp-mediated drug efflux [18,26].
Fig. 7 – Plasma concentration–time profiles of (a) ITZ and (b) OH-ITZ after oral administration of self-made tablets and
Sporanox® to male beagle dogs. (mean ± SD, n = 6).
Table 1 – Pharmacokinetic parameters of ITZ and OH-
ITZ after oral administration of Itraconazole tablets and




AUC0–96h, ITZ μg/k h 7068.8 ± 3638.5 3347.4 ± 2067.0
AUC0–96h,OH-ITZ μg/k h 21,855.1 ± 7338.3 12,804.8 ± 4598.9
Cmax, ITZ μg/k 342.4 ± 121.6 257.5 ± 156.2
Cmax, OH-ITZ μg/k 342.0 ± 136.4 267.3 ± 105.8
Tmax, ITZ h 1.3 ± 0.6 2.8 ± 1.8
Tmax, OH-ITZ h 7.7 ± 1.9 8.3 ± 2.3
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These two key factors markedly promoted the absorption of
ITZ in vivo.
The uptake of micelles in the intestine and the extent of
drug absorption increased with the reduction of particle size
[27]. It has been reported that size is an important parameter
controlling the internalization of nanoparticles into epithelia
of the GI tract, and nanoparticles less than 100 nm in diam-
eter have been detected in the intestinal mucosa and gut-
associated lymphoid tissues and 500 nm particles have been
found in the intestinal tissues, while particles larger than 1 μm
in diameter and have been found only in the Peyer’s patches
[28,29]. In this study, the size of the drug-loaded micelles with
Soluplus® was found to be about 70 nm (smaller than 100 nm)
and have met the requirement of uptake by gastrointestinal
tissue to achieve a better drug absorption [17].
All of the results obtained confirmed the advantage of mi-
celles formed by Soluplus®, contributing to the high
bioavailability of ITZ.The pharmacokinetic parameters in beagle
dogs are a strong evidence to support the viewpoints that were
discussed earlier: micelles formed by Soluplus® in the gastro-
intestinal tract maintained supersaturation of ITZ and
contributed to the absorption of ITZ in vivo.
In addition, before micelle formation in the gastrointesti-
nal tract, extrudates were well protected in the tablets as a solid
solution during long-term storage. Since drug absorption in the
intestine lasts for only a few hours, therefore, unlike other con-
ventional polymeric micelle solutions, there is no need to take
the long-term storage stability of micelle solutions into
consideration.
In summary, this marked improvement in the pharmaco-
kinetic parameters of ITZ and OH-ITZ in the tablets after oral
administration could be explained by a combination of the fol-
lowing effects: (1) the amorphous state ITZ dispersed
homogeneously in the tablets increases the dissolution rate
and extent of ITZ, (2) Soluplus® micelles possess a signifi-
cantly low CMC; thus, Soluplus® micelles remain intact even
when suffering from severe dilution and pH change in the gas-
trointestinal tract [30]. Soluplus® also acts as a stabilizer of
supersaturation upon drug release and prevents precipita-
tion in the intestine, (3) the hydrophilic shell of micelles is an
advantage for passing through the ABL, (4) reduced elimina-
tion of ITZ due to the inhibitory effect of Soluplus® on intestinal
P-gp drug efflux, (5) the micelles (smaller than 100 nm) seem
to produce an efficient interfacial interaction with the cell mem-
brane, such as phagocytosis and pinocytosis, (6) as a nanosized
drug delivery system, Soluplus® micelles reduce the uptake by
the mononuclear phagocyte system (MPS), allowing longer cir-
culation in the body [31];
Fig. 8 – Representation of how micelles can permeate the intestinal membrane.
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5. Conclusions
This study demonstrates that the self-assembly of Soluplus®
in aqueous solutions as well as the micelles formed in the gas-
trointestinal tract by solid dispersions through HME represent
a promising vehicle for the oral delivery of poorly water-
soluble compounds. Supersaturation maintained by the micelles
increases the concentration in the intestinal cavity. Drugs in
the micelles are carried through the ABL, contributing to the
absorption by passive transportation across biological mem-
branes, allowing the uptake of intact micelles through
pinocytosis and the presence of Soluplus® inhibit the drug efflux
by P-gp in the intestinal tract. This formulation increases the
bioavailability in the gastrointestinal tract and leads to higher
concentrations in the plasma which is a great advantage com-
pared with Sporanox®.
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